Compare · KRRO vs NVO
KRRO vs NVO
Side-by-side comparison of Korro Bio Inc. (KRRO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRRO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 1261.1x KRRO ($176.7M).
- KRRO has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Korro Bio Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $176.7M
- $222.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KRRO
- Chief Scientific Officer Vincent Loic A was granted 7,500 shares, increasing direct ownership by 41% to 25,797 units (SEC Form 4)
- Senior Vice President, Finance Dolan Oliver was granted 5,500 shares, increasing direct ownership by 30% to 23,599 units (SEC Form 4)
- General Counsel Cerio Jeffrey was granted 6,500 shares, increasing direct ownership by 18% to 41,793 units (SEC Form 4)
- Chief Operating Officer Chappell Todd was granted 7,500 shares, increasing direct ownership by 44% to 24,464 units (SEC Form 4)
- Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Formela Jean Francois sold $1,542,970 worth of shares (110,023 units at $14.02) as part of a pre-agreed trading plan (SEC Form 4)
- Director Formela Jean Francois sold $2,458,582 worth of shares (171,405 units at $14.34) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Chappell Todd sold $34,309 worth of shares (3,168 units at $10.83), decreasing direct ownership by 16% to 16,964 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Vincent Loic A sold $37,017 worth of shares (3,418 units at $10.83), decreasing direct ownership by 16% to 18,297 units (SEC Form 4) (withholding obligation)
- General Counsel Cerio Jeffrey sold $71,575 worth of shares (6,609 units at $10.83), decreasing direct ownership by 16% to 35,293 units (SEC Form 4) (tax liability)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S